| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12185-012-1015-Z |
| P698 | PubMed publication ID | 22314304 |
| P2093 | author name string | Hideto Matsui | |
| P2860 | cites work | Origins of circulating endothelial cells and endothelial outgrowth from blood | Q24599869 |
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. | Q31055278 | ||
| Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors | Q33345019 | ||
| Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A | Q33356962 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| The hemophilias--from royal genes to gene therapy | Q34276237 | ||
| Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice | Q34675871 | ||
| Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy | Q34767834 | ||
| Haemophilias A and B. | Q35143113 | ||
| The World Federation of Hemophilia: 40 years of improving haemophilia care worldwide | Q35642566 | ||
| Central venous access devices in haemophilia | Q35666735 | ||
| Preclinical animal models for hemophilia gene therapy: predictive value and limitations | Q35760785 | ||
| Optimizing factor prophylaxis for the haemophilia population: where do we stand? | Q35915686 | ||
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion | Q38520320 | ||
| In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs | Q41524708 | ||
| A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. | Q42709633 | ||
| In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. | Q45861338 | ||
| Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector | Q45862203 | ||
| Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing | Q45863479 | ||
| A canine model of hemophilic (factor VIII:C deficiency) bleeding | Q45864385 | ||
| Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors | Q45869403 | ||
| Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. | Q45869438 | ||
| The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary | Q45874637 | ||
| Gene therapy. Side effects sideline hemophilia trial | Q45875809 | ||
| Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. | Q45877779 | ||
| A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells | Q45885457 | ||
| Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy | Q45886628 | ||
| The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo | Q45889365 | ||
| Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C | Q71078437 | ||
| Hemophilia A | Q72652433 | ||
| The canine factor VIII cDNA and 5' flanking sequence | Q74286665 | ||
| P433 | issue | 2 | |
| P921 | main subject | hemophilia A | Q2092064 |
| endothelium | Q111140 | ||
| hemophilia | Q134003 | ||
| P304 | page(s) | 119-124 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | International Journal of Hematology | Q6051416 |
| P1476 | title | Endothelial progenitor cell-based therapy for hemophilia A. | |
| P478 | volume | 95 |
| Q36552555 | Advanced therapies for the treatment of hemophilia: future perspectives |
| Q37630979 | An effective ex-vivo approach for inducing endothelial progenitor cells from umbilical cord blood CD34+ cells |
| Q49241266 | Evaluation of ex vivo produced endothelial progenitor cells for autologous transplantation in primates |
| Q38076953 | Hemophilia clinical gene therapy: brief review |
| Q57720975 | In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A |
| Q61445701 | Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells |
| Q64104842 | Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs |
Search more.